Durgical
EN
Open the app

Vortioxetine

  • Atypical antidepressantsAtypical antidepressants

A 'multimodal' antidepressant: it blocks serotonin reuptake and acts on several serotonin receptors. Nausea is the main early side effect.

Updated

Quick facts

Group
Atypical antidepressants
Target
Serotonin transporter (SERT); also 5-HT3, 5-HT7 and 5-HT1D receptors (antagonist) and 5-HT1A and 5-HT1B (partial agonist); the 5-HT3A receptor is shown
Used for
Major depressive disorder in adults
Key effects
Nausea and vomiting · Constipation · Unusual dreams
Monitor
Mood and suicidal thoughts · Bleeding
ATC
N06AX26

No doses: the clinician sets them by the current guideline.

Mechanism of action

The figure shows vortioxetine bound to the extracellular domain of the human 5-HT3A receptor, one of the serotonin receptors it blocks.

Target in 3D: Serotonin transporter (SERT); also 5-HT3, 5-HT7 and 5-HT1D receptors (antagonist) and 5-HT1A and 5-HT1B (partial agonist); the 5-HT3A receptor is shown. PDB structure 8BLB (RCSB PDB, public domain). View the structure at RCSB PDB

Vortioxetine is a potent inhibitor of the serotonin transporter, as SSRIs are, and also acts directly on serotonin receptors: it is a partial agonist at 5-HT1A and 5-HT1B receptors and an antagonist at 5-HT1D, 5-HT3 and 5-HT7 receptors. The antidepressant effect builds over weeks.

  1. Blocks the serotonin transporter (like an SSRI)
  2. Blocks 5-HT3, 5-HT7 and 5-HT1D receptors
  3. Partial agonist at 5-HT1A and 5-HT1B receptors
  4. Mood improves over several weeks

Indications

Adverse effects

Common

  • Nausea and vomiting
  • Constipation
  • Unusual dreams
  • Sexual problems (lower libido, delayed orgasm or ejaculation)

Contraindications

  • MAO inhibitors (including linezolid and intravenous methylene blue) now or within two weeks
  • Hypersensitivity to vortioxetine

Key interactions

MAO inhibitors
Serotonin syndrome; at least 21 days must pass after stopping vortioxetine before an MAOI is started.
St John's wort, tryptophan and other serotonergic drugs
Higher risk of serotonin syndrome.
Alcohol
Worse side effects.

What is monitored

  • Mood and suicidal thoughts, especially in the first months
  • Bleeding, particularly with anticoagulants or antiplatelets
  • Symptoms of serotonin syndrome when other serotonergic drugs are added

Administration and safety

  • Oral tablet once a day at about the same time.
  • Not stopped abruptly: headache, mood change, dizziness or tingling can follow.
  • The dose is changed only by the prescriber.

Pregnancy and breastfeeding

Pregnancy or plans for pregnancy are discussed with the prescriber, weighing untreated depression against drug exposure.

Nursing care

  • Before: ask about MAOI use, bleeding problems and seizures.
  • During: ask about nausea (usually early) and sexual side effects, which can lead to stopping.
  • Watch mood and suicidal thoughts; involve family.
  • Teach the signs of serotonin syndrome and of angle-closure glaucoma.

Pharmacokinetics

Absorption
Oral tablet, once a day, with or without food.
Onset and duration
Full benefit may take several weeks.

Test yourself

Think of the answer, then tap the question to see it.

Why is vortioxetine called 'multimodal'?

It inhibits the serotonin transporter and also acts directly on several serotonin receptors (antagonist at 5-HT3, 5-HT7, 5-HT1D; partial agonist at 5-HT1A and 5-HT1B).

What is its most common early side effect?

Nausea.

How long must one wait after stopping vortioxetine before starting an MAO inhibitor?

At least 21 days.

Add to my cards (3)

More Pharmacology questions →

Connections

← Back to the class: Atypical antidepressants

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Vortioxetine: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); Human serotonin 5-HT3A receptor in complex with vortioxetine (nanodiscs, ECD, active/distorted conformation) (RCSB Protein Data Bank, 2024); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.